Differential Effects of Zanubrutinib and Ibrutinib on Neutrophil Antifungal Functions: Insights from Live-Cell Imaging
Journal of Innate Immunity · 2026-08-14 · 18 (1) · 448-460
DOI: 10.1159/jin/adhag001 ↗Abstract
Introduction: Bruton tyrosine kinase inhibitors (BTKi) impair anti-Aspergillus immune responses and increase the risk of invasive fungal infections (IFI). More selective second-generation BTKi have fewer off-target effects thus a better tolerance than ibrutinib. Though clinical data suggest the incidence of IFI is lower with second-generation BTKi, whether they have less impact on antifungal immunity remains unclear. Methods: We studied the activation phenotype and behavior of human neutrophils in vitro with fungal extracts or living Aspergillus fumigatus in the presence of either ibrutinib or zanubrutinib, a more selective second-generation BTKi, using various approaches, including live microscopy. Results: Both molecules inhibited the activation-induced phenotypic changes in neutrophils following exposure to hyphae. Similarly, ibrutinib and zanubrutinib impaired neutrophil-mediated inhibition of conidia germination. By contrast, live neutrophil imaging showed that neutrophils exposed to ibrutinib but not zanubrutinib kept a round morphology, suggesting a defective activation, were less mobile, and showed impaired conidia phagocytosis. Conclusion: We confirm here that ibrutinib and zanubrutinib inhibit neutrophil antifungal activity, strongly suggesting that BTK plays a central role. However, subtle differences between ibrutinib and zanubrutinib were evidenced using live microscopy, which might indicate additional off-target effects, and potentially partially explain the lower incidence of IFI with zanubrutinib; the clinical relevance remains to be determined.
EUVIMED